{domain:"www.qualitydigest.com",server:"169.47.211.87"} Skip to main content

User account menu
Main navigation
  • Topics
    • Customer Care
    • FDA Compliance
    • Healthcare
    • Innovation
    • Lean
    • Management
    • Metrology
    • Operations
    • Risk Management
    • Six Sigma
    • Standards
    • Statistics
    • Supply Chain
    • Sustainability
    • Training
  • Videos/Webinars
    • All videos
    • Product Demos
    • Webinars
  • Advertise
    • Advertise
    • Submit B2B Press Release
    • Write for us
  • Metrology Hub
  • Training
  • Subscribe
  • Log in
Mobile Menu
  • Home
  • Topics
    • 3D Metrology-CMSC
    • Customer Care
    • FDA Compliance
    • Healthcare
    • Innovation
    • Lean
    • Management
    • Metrology
    • Operations
    • Risk Management
    • Six Sigma
    • Standards
    • Statistics
    • Supply Chain
    • Sustainability
    • Training
  • Login / Subscribe
  • More...
    • All Features
    • All News
    • All Videos
    • Contact
    • Training

What Should Really Trigger a CAPA?

CAPA-worthy or CAPA-happy?

Sara Adams
Tue, 02/22/2022 - 12:03
  • Comment
  • RSS

Social Sharing block

  • Print
  • Add new comment
Body

Corrective and preventive action (CAPA) is often a thorn in the side of medical device manufacturers. Problems with CAPA top the list of reasons for 483s and warning letters from the FDA year after year, and many companies struggle to identify when they should even initiate a CAPA.

ADVERTISEMENT

When companies are uncertain about what should trigger a CAPA, they tend to make one of two mistakes:
• They get “CAPA happy.” In this case, every incident is treated as CAPA-worthy, which leads to mountains of paperwork and enormous stress. As the CAPAs pile up, the backlog slows progress to a crawl, and the company may suffer “death by CAPA.”
• They ignore CAPA-worthy issues. On the other hand, some companies don’t escalate issues to CAPA when action is warranted. This underuse of the CAPA process leaves them vulnerable to 483s and warning letters from FDA, and has an adverse effect on the safety and efficacy of their devices.

 …

Want to continue?
Log in or create a FREE account.
Enter your username or email address
Enter the password that accompanies your username.
By logging in you agree to receive communication from Quality Digest. Privacy Policy.
Create a FREE account
Forgot My Password

Comments

Submitted by Cesar Rios (not verified) on Mon, 02/21/2022 - 08:32

COMMENT

EXCELLENT ANALYSIS... thank you

  • Reply

Add new comment

Image CAPTCHA
Enter the characters shown in the image.
Please login to comment.
      

© 2025 Quality Digest. Copyright on content held by Quality Digest or by individual authors. Contact Quality Digest for reprint information.
“Quality Digest" is a trademark owned by Quality Circle Institute Inc.

footer
  • Home
  • Print QD: 1995-2008
  • Print QD: 2008-2009
  • Videos
  • Privacy Policy
  • Write for us
footer second menu
  • Subscribe to Quality Digest
  • About Us
  • Contact Us